Eintrag weiter verarbeiten
Prognostic Factors for Survival of Patients with Stage IV Renal Cell Carcinoma
Gespeichert in:
| Zeitschriftentitel: | Clinical Cancer Research |
|---|---|
| Personen und Körperschaften: | , , |
| In: | Clinical Cancer Research, 10, 2004, 18, S. 6302S-6303S |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
American Association for Cancer Research (AACR)
|
| Schlagwörter: |
| author_facet |
Motzer, Robert J. Bacik, Jennifer Mazumdar, Madhu Motzer, Robert J. Bacik, Jennifer Mazumdar, Madhu |
|---|---|
| author |
Motzer, Robert J. Bacik, Jennifer Mazumdar, Madhu |
| spellingShingle |
Motzer, Robert J. Bacik, Jennifer Mazumdar, Madhu Clinical Cancer Research Prognostic Factors for Survival of Patients with Stage IV Renal Cell Carcinoma Cancer Research Oncology |
| author_sort |
motzer, robert j. |
| spelling |
Motzer, Robert J. Bacik, Jennifer Mazumdar, Madhu 1078-0432 1557-3265 American Association for Cancer Research (AACR) Cancer Research Oncology http://dx.doi.org/10.1158/1078-0432.ccr-040031 <jats:title>Abstract</jats:title> <jats:p>Prospective identification of patients with stage IV renal cell carcinoma more likely to benefit from cytokine therapy could be used as a stratification factor in Phase III trials and in risk-directed therapy. The relationship between pretreatment clinical features and survival was evaluated in patients treated in Phase II and III clinical trials for metastatic renal cell carcinoma at the Memorial Sloan-Kettering Cancer Center. The first analysis was performed in 670 patients treated with cytokines or chemotherapy, and a multivariate model was created to predict survival. Studies that followed addressed four topics: (1) the survival of patients given interferon α as first-line therapy, (2) a comparison of survival for patients treated with chemotherapy versus cytokine therapy, (3) survival of patients with nonclear cell histologic features, and (4) survival of patients treated with a second-line therapy. Prognostic models based on pretreatment clinical and laboratory variables can help identify patients more likely to benefit from standard therapies, as well as assist in the interpretation of drug effectiveness in Phase II clinical trials. Investigations into new prognostic factors based on tumor biology are needed and of high priority.</jats:p> Prognostic Factors for Survival of Patients with Stage IV Renal Cell Carcinoma Clinical Cancer Research |
| doi_str_mv |
10.1158/1078-0432.ccr-040031 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8xMDc4LTA0MzIuY2NyLTA0MDAzMQ |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8xMDc4LTA0MzIuY2NyLTA0MDAzMQ |
| institution |
DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 |
| imprint |
American Association for Cancer Research (AACR), 2004 |
| imprint_str_mv |
American Association for Cancer Research (AACR), 2004 |
| issn |
1078-0432 1557-3265 |
| issn_str_mv |
1078-0432 1557-3265 |
| language |
English |
| mega_collection |
American Association for Cancer Research (AACR) (CrossRef) |
| match_str |
motzer2004prognosticfactorsforsurvivalofpatientswithstageivrenalcellcarcinoma |
| publishDateSort |
2004 |
| publisher |
American Association for Cancer Research (AACR) |
| recordtype |
ai |
| record_format |
ai |
| series |
Clinical Cancer Research |
| source_id |
49 |
| title |
Prognostic Factors for Survival of Patients with Stage IV Renal Cell Carcinoma |
| title_unstemmed |
Prognostic Factors for Survival of Patients with Stage IV Renal Cell Carcinoma |
| title_full |
Prognostic Factors for Survival of Patients with Stage IV Renal Cell Carcinoma |
| title_fullStr |
Prognostic Factors for Survival of Patients with Stage IV Renal Cell Carcinoma |
| title_full_unstemmed |
Prognostic Factors for Survival of Patients with Stage IV Renal Cell Carcinoma |
| title_short |
Prognostic Factors for Survival of Patients with Stage IV Renal Cell Carcinoma |
| title_sort |
prognostic factors for survival of patients with stage iv renal cell carcinoma |
| topic |
Cancer Research Oncology |
| url |
http://dx.doi.org/10.1158/1078-0432.ccr-040031 |
| publishDate |
2004 |
| physical |
6302S-6303S |
| description |
<jats:title>Abstract</jats:title>
<jats:p>Prospective identification of patients with stage IV renal cell carcinoma more likely to benefit from cytokine therapy could be used as a stratification factor in Phase III trials and in risk-directed therapy. The relationship between pretreatment clinical features and survival was evaluated in patients treated in Phase II and III clinical trials for metastatic renal cell carcinoma at the Memorial Sloan-Kettering Cancer Center. The first analysis was performed in 670 patients treated with cytokines or chemotherapy, and a multivariate model was created to predict survival. Studies that followed addressed four topics: (1) the survival of patients given interferon α as first-line therapy, (2) a comparison of survival for patients treated with chemotherapy versus cytokine therapy, (3) survival of patients with nonclear cell histologic features, and (4) survival of patients treated with a second-line therapy. Prognostic models based on pretreatment clinical and laboratory variables can help identify patients more likely to benefit from standard therapies, as well as assist in the interpretation of drug effectiveness in Phase II clinical trials. Investigations into new prognostic factors based on tumor biology are needed and of high priority.</jats:p> |
| container_issue |
18 |
| container_start_page |
0 |
| container_title |
Clinical Cancer Research |
| container_volume |
10 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792344414136303625 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T17:07:10.691Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Prognostic+Factors+for+Survival+of+Patients+with+Stage+IV+Renal+Cell+Carcinoma&rft.date=2004-09-15&genre=article&issn=1557-3265&volume=10&issue=18&pages=6302S-6303S&jtitle=Clinical+Cancer+Research&atitle=Prognostic+Factors+for+Survival+of+Patients+with+Stage+IV+Renal+Cell+Carcinoma&aulast=Mazumdar&aufirst=Madhu&rft_id=info%3Adoi%2F10.1158%2F1078-0432.ccr-040031&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792344414136303625 |
| author | Motzer, Robert J., Bacik, Jennifer, Mazumdar, Madhu |
| author_facet | Motzer, Robert J., Bacik, Jennifer, Mazumdar, Madhu, Motzer, Robert J., Bacik, Jennifer, Mazumdar, Madhu |
| author_sort | motzer, robert j. |
| container_issue | 18 |
| container_start_page | 0 |
| container_title | Clinical Cancer Research |
| container_volume | 10 |
| description | <jats:title>Abstract</jats:title> <jats:p>Prospective identification of patients with stage IV renal cell carcinoma more likely to benefit from cytokine therapy could be used as a stratification factor in Phase III trials and in risk-directed therapy. The relationship between pretreatment clinical features and survival was evaluated in patients treated in Phase II and III clinical trials for metastatic renal cell carcinoma at the Memorial Sloan-Kettering Cancer Center. The first analysis was performed in 670 patients treated with cytokines or chemotherapy, and a multivariate model was created to predict survival. Studies that followed addressed four topics: (1) the survival of patients given interferon α as first-line therapy, (2) a comparison of survival for patients treated with chemotherapy versus cytokine therapy, (3) survival of patients with nonclear cell histologic features, and (4) survival of patients treated with a second-line therapy. Prognostic models based on pretreatment clinical and laboratory variables can help identify patients more likely to benefit from standard therapies, as well as assist in the interpretation of drug effectiveness in Phase II clinical trials. Investigations into new prognostic factors based on tumor biology are needed and of high priority.</jats:p> |
| doi_str_mv | 10.1158/1078-0432.ccr-040031 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8xMDc4LTA0MzIuY2NyLTA0MDAzMQ |
| imprint | American Association for Cancer Research (AACR), 2004 |
| imprint_str_mv | American Association for Cancer Research (AACR), 2004 |
| institution | DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4 |
| issn | 1078-0432, 1557-3265 |
| issn_str_mv | 1078-0432, 1557-3265 |
| language | English |
| last_indexed | 2024-03-01T17:07:10.691Z |
| match_str | motzer2004prognosticfactorsforsurvivalofpatientswithstageivrenalcellcarcinoma |
| mega_collection | American Association for Cancer Research (AACR) (CrossRef) |
| physical | 6302S-6303S |
| publishDate | 2004 |
| publishDateSort | 2004 |
| publisher | American Association for Cancer Research (AACR) |
| record_format | ai |
| recordtype | ai |
| series | Clinical Cancer Research |
| source_id | 49 |
| spelling | Motzer, Robert J. Bacik, Jennifer Mazumdar, Madhu 1078-0432 1557-3265 American Association for Cancer Research (AACR) Cancer Research Oncology http://dx.doi.org/10.1158/1078-0432.ccr-040031 <jats:title>Abstract</jats:title> <jats:p>Prospective identification of patients with stage IV renal cell carcinoma more likely to benefit from cytokine therapy could be used as a stratification factor in Phase III trials and in risk-directed therapy. The relationship between pretreatment clinical features and survival was evaluated in patients treated in Phase II and III clinical trials for metastatic renal cell carcinoma at the Memorial Sloan-Kettering Cancer Center. The first analysis was performed in 670 patients treated with cytokines or chemotherapy, and a multivariate model was created to predict survival. Studies that followed addressed four topics: (1) the survival of patients given interferon α as first-line therapy, (2) a comparison of survival for patients treated with chemotherapy versus cytokine therapy, (3) survival of patients with nonclear cell histologic features, and (4) survival of patients treated with a second-line therapy. Prognostic models based on pretreatment clinical and laboratory variables can help identify patients more likely to benefit from standard therapies, as well as assist in the interpretation of drug effectiveness in Phase II clinical trials. Investigations into new prognostic factors based on tumor biology are needed and of high priority.</jats:p> Prognostic Factors for Survival of Patients with Stage IV Renal Cell Carcinoma Clinical Cancer Research |
| spellingShingle | Motzer, Robert J., Bacik, Jennifer, Mazumdar, Madhu, Clinical Cancer Research, Prognostic Factors for Survival of Patients with Stage IV Renal Cell Carcinoma, Cancer Research, Oncology |
| title | Prognostic Factors for Survival of Patients with Stage IV Renal Cell Carcinoma |
| title_full | Prognostic Factors for Survival of Patients with Stage IV Renal Cell Carcinoma |
| title_fullStr | Prognostic Factors for Survival of Patients with Stage IV Renal Cell Carcinoma |
| title_full_unstemmed | Prognostic Factors for Survival of Patients with Stage IV Renal Cell Carcinoma |
| title_short | Prognostic Factors for Survival of Patients with Stage IV Renal Cell Carcinoma |
| title_sort | prognostic factors for survival of patients with stage iv renal cell carcinoma |
| title_unstemmed | Prognostic Factors for Survival of Patients with Stage IV Renal Cell Carcinoma |
| topic | Cancer Research, Oncology |
| url | http://dx.doi.org/10.1158/1078-0432.ccr-040031 |